NEW YORK (GenomeWeb News) – With uncertainty over future National Institutes of Health funding and concerns over austerity measures in Europe, investors have recently cooled on the stocks of genomics tools firms.

Following a strong January and modest gains for the remainder of the first quarter, the stocks of genomics tools firms and some molecular diagnostics companies have slumped over the past couple of months, though part of that can be attributed to bearish trends in the broader stock market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.